

October 30, 2021

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
--	--

Dear Sir,

**Sub: Intimation of Board Meeting.**

We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on **Monday, November 8, 2021** to consider and approve inter alia, the following:


1. Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2021 and
2. Payment of Second Interim Dividend, if any, for the financial year 2021-22.

Further to our letter dated September 28, 2021 informing the closure of Trading Window of the Company from October 1, 2021 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2021, we inform you that the Trading Window will remain closed up to November 10, 2021 and shall be re-opened on November 11, 2021.

Please take the information on record.

Thanking you,

Yours faithfully,  
For **AUROBINDO PHARMA LIMITED**

  
B. Adi Reddy  
Company Secretary